Standards for Reducing Risks Associated with ePMA for SACT

It is with great pleasure to announce that the BOPA Standards for Reducing Risks Associated with ePMA for SACT have been updated and can be found in the publication section of the members only section of the website.
 
These BOPA Standards for Reducing Risks Associated with Electronic Prescribing and Medicines Administration Systems (ePMA) for Systemic Anti-Cancer Therapies (SACT) outlines steps that can be considered to be best practice in reducing the risks of errors arising from the introduction and use of e-prescribing systems for SACT within organisations.
 
If you have any queries please direct them to [email protected]
 

Latest News

By BOPA Research Committee on 27th April 2025

SURVEY: Understanding Clinicians’ perceptions of a Decision Support tool for Lung Cancer Treatment

Dear BOPA member, Tarini Deleep and Dr Pinkie Chambers from University College London are developing a risk prediction model to help identify patients with incurable Non Small Cell Lung Cancer,…

Read article
By BOPA on 27th April 2025

Further monographs for use of immunosuppressants in Immune-related adverse events (irAEs)

Earlier this year the BOPA Immunotherapy Group wrote, and published, four monographs to help health care professionals care for patients with immune-related adverse events. As a group we are pleased…

Read article
By BOPA Committee on 27th April 2025

Women for Oncology UK Spring Webinar

The Spring webinar for Women for Oncology UK is on the 16th May, to sign up click the link below. Women For Oncology UK Spring Webinar Tickets, Wed 14 May…

Read article
By BOPA Executive Committee on 25th April 2025

NICE TA: Ribociclib with an aromatase inhibitor can be used as an option for the adjuvant treatment of hormone receptor-positive, HER2-negative, early breast cancer at high risk of recurrence in adults.

BOPA have been involved with the following NICE TA: Ribociclib with an aromatase inhibitor can be used as an option for the adjuvant treatment of hormone receptor-positive, HER2-negative, early breast cancer…

Read article